Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Intel: Intragastric Balloons And Other Innovations To Inflate Weight Loss Devices Market

Executive Summary

The global market for minimally invasive weight loss devices is expected to grow to $290m by 2021, a CAGR of 16%, driven in large part by the rising obesity epidemic and associated Type 2 diabetes. Meddevicetracker expects that enhancements and innovations, particularly in the growing intragastric balloon market, and emerging technologies by smaller companies, will lead the growth in the overall weight loss devices market. In this feature, we'll take a closer look at the overall market and regional landscape and take a deep dive into the fastest-growing intragastric balloon segment, providing key insights from a bariatric surgeon on the pros and cons of these technologies.

You may also be interested in...



Starts & Stops: Check-Cap Starts US Trial; Venous Valve Study Begins; CorMatrix Looks At ‘Living’ Tricuspid Valve

Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Feb. 11 through Feb. 24, including announcements from CorMatrix Cardiovascular, Hancock Jaffe Laboratories, Toray Industries, Spectral Medical, GI Dynamics, and Check-Cap.

Obesity Firm Allurion Preps For Global Expansion, US Trial With Changes At Top

Intragastric balloon-maker Allurion is making some major changes in its executive suite to support its plan to expand its market reach.

EnteroMedics Inflates Neuromod-Obesity Offering With ReShape Balloon

The deal, worth $61m in cash and stock, will add ReShape's Dual Weight Loss Balloon to EnteroMedics' vBloc neurometabolic therapy and Gastric Vest System for the treatment of obesity.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT121687

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel